FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

View source ↗

Summary

FDA approves Lisraya (brepocitinib) tablets as the first oral treatment indicated for dermatomyositis in adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis

Drugs mentioned

• Lisraya (brepocitinib)

Snippet

The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets for the treatment of dermatomyositis in adults.